• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant.p16-Leiden种系变体携带者患癌的前瞻性风险及烟草使用的影响。
Eur J Hum Genet. 2015 May;23(5):711-4. doi: 10.1038/ejhg.2014.187. Epub 2014 Sep 17.
2
Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.全国范围内携带p16-Leiden种系突变的队列中胰腺癌相关基因多态性;一项病例对照研究。
BMC Res Notes. 2015 Jun 26;8:264. doi: 10.1186/s13104-015-1235-4.
3
High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.CDKN2A 突变阳性黑色素瘤家族中患烟草相关癌症的高风险。
J Med Genet. 2014 Aug;51(8):545-52. doi: 10.1136/jmedgenet-2014-102320. Epub 2014 Jun 16.
4
Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.CDKN2A-p16-Leiden 突变携带者发生多种胰腺癌的风险。
Eur J Hum Genet. 2018 Aug;26(8):1227-1229. doi: 10.1038/s41431-018-0170-y. Epub 2018 May 16.
5
Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.评估 TERT/CLPTM1L 多癌症风险区域内的单个 SNP 作为荷兰 CDKN2A 突变携带者患胰腺癌和黑色素瘤风险的遗传修饰因子。
Fam Cancer. 2019 Oct;18(4):439-444. doi: 10.1007/s10689-019-00137-5.
6
A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.一种罕见的种系 CDKN2A 变异(47T>G;p16-L16R)通过降低细胞周期抑制作用使携带者易患胰腺癌。
J Biol Chem. 2021 Jan-Jun;296:100634. doi: 10.1016/j.jbc.2021.100634. Epub 2021 Apr 3.
7
Prospective risk of cancer in CDKN2A germline mutation carriers.CDKN2A种系突变携带者患癌的前瞻性风险。
J Med Genet. 2004 Jun;41(6):421-4. doi: 10.1136/jmg.2004.019349.
8
Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).与p16基因特定19号外显子缺失(p16-Leiden)相关的家族性非典型多发性痣黑色素瘤家族中患胰腺癌的风险。
Int J Cancer. 2000 Sep 15;87(6):809-11.
9
Development of esophageal squamous cell cancer in patients with FAMMM syndrome: Two clinical reports.FAMMM综合征患者食管鳞状细胞癌的发生:两份临床报告。
Eur J Med Genet. 2020 Mar;63(3):103840. doi: 10.1016/j.ejmg.2020.103840. Epub 2020 Jan 7.
10
High Growth Rate of Pancreatic Ductal Adenocarcinoma in Mutation Carriers.携带突变的胰腺导管腺癌的高增长率。
Cancer Prev Res (Phila). 2018 Sep;11(9):551-556. doi: 10.1158/1940-6207.CAPR-18-0035. Epub 2018 Jul 10.

引用本文的文献

1
Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.了解胰腺导管腺癌的遗传图谱以支持个性化医疗:一项系统综述。
Cancers (Basel). 2023 Dec 21;16(1):56. doi: 10.3390/cancers16010056.
2
Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in and Pancreatic Cancer.基因水平与具有和不具有胚系突变的 和胰腺癌患者的关联。
JCO Precis Oncol. 2022 Nov;6:e2200145. doi: 10.1200/PO.22.00145.
3
Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers.转录本(p16/p14ARF)改变对 CDKN2A 种系致病性变异携带者癌症风险的影响。
JNCI Cancer Spectr. 2022 Nov 1;6(6). doi: 10.1093/jncics/pkac074.
4
Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers.CDKN2A 基因突变携带者和非携带者纳入家族性黑色素瘤皮肤监测计划前后的黑色素瘤特异性生存。
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):284-292. doi: 10.1111/jdv.18589. Epub 2022 Oct 1.
5
Inherited Pancreatic Cancer Syndromes and High-Risk Screening.遗传性胰腺癌综合征与高危人群筛查
Surg Oncol Clin N Am. 2021 Oct;30(4):773-786. doi: 10.1016/j.soc.2021.06.002. Epub 2021 Jul 22.
6
The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go.2020 年胰腺导管腺癌的遗传学研究:突飞猛进,但仍任重道远。
Mod Pathol. 2020 Dec;33(12):2544-2563. doi: 10.1038/s41379-020-0629-6. Epub 2020 Jul 23.
7
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma.多学科护理标准和胰腺导管腺癌的最新进展。
CA Cancer J Clin. 2020 Sep;70(5):375-403. doi: 10.3322/caac.21626. Epub 2020 Jul 19.
8
Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.评估 TERT/CLPTM1L 多癌症风险区域内的单个 SNP 作为荷兰 CDKN2A 突变携带者患胰腺癌和黑色素瘤风险的遗传修饰因子。
Fam Cancer. 2019 Oct;18(4):439-444. doi: 10.1007/s10689-019-00137-5.
9
Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013-2018).家族性黑色素瘤患者导向研究的主要临床进展(2013 - 2018年)进展报告
Fam Cancer. 2019 Apr;18(2):267-271. doi: 10.1007/s10689-018-00115-3.
10
Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.在一个大型荷兰非 CDKN2A/CDK4 黑色素瘤家族队列中对已确定和候选黑色素瘤易感性基因进行多基因panel 测序。
Int J Cancer. 2019 May 15;144(10):2453-2464. doi: 10.1002/ijc.31984. Epub 2019 Jan 21.

本文引用的文献

1
Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry.荷兰基于组织学分级的神经内分泌肿瘤发病率和生存率:癌症登记 20 年经验。
Eur J Cancer. 2013 May;49(8):1975-83. doi: 10.1016/j.ejca.2012.12.022. Epub 2013 Jan 23.
2
Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.CDKN2A 突变携带者一级亲属中非黑色素瘤癌症的风险。
J Natl Cancer Inst. 2012 Jun 20;104(12):953-6. doi: 10.1093/jnci/djs221. Epub 2012 Apr 24.
3
Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas.与头颈部鳞状细胞癌和黑色素瘤相关的新型种系 CDKN2A 突变。
Head Neck. 2013 Mar;35(3):E80-4. doi: 10.1002/hed.21911. Epub 2011 Nov 15.
4
Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A.家族性 CDKN2A 胚系突变恶性黑色素瘤的临床和组织学特征。
J Am Acad Dermatol. 2011 Aug;65(2):281-288. doi: 10.1016/j.jaad.2010.06.044. Epub 2011 May 12.
5
Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.磁共振成像监测在 p16-Leiden 突变携带者中检测早期胰腺癌。
Gastroenterology. 2011 Mar;140(3):850-6. doi: 10.1053/j.gastro.2010.11.048. Epub 2010 Dec 1.
6
Head and neck squamous cell carcinoma in FAMMM syndrome.家族性黏液血管纤维瘤病综合征中的头颈部鳞状细胞癌。
Head Neck. 2009 Nov;31(11):1524-7. doi: 10.1002/hed.21050.
7
Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.携带细胞周期蛋白依赖性激酶抑制剂2A(CDKN2A)始祖突变(p16-莱顿突变)的阳性黑色素瘤家族中,除黑色素瘤外其他癌症的发病风险增加。
Clin Cancer Res. 2008 Nov 1;14(21):7151-7. doi: 10.1158/1078-0432.CCR-08-0403.
8
Epidemiology of sarcoidosis: recent advances and future prospects.结节病的流行病学:最新进展与未来展望
Semin Respir Crit Care Med. 2007 Feb;28(1):22-35. doi: 10.1055/s-2007-970331.
9
Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system.胃肠胰系统散发性神经内分泌肿瘤的分子通路分析
Int J Cancer. 2007 May 15;120(10):2157-64. doi: 10.1002/ijc.22569.
10
Prospective risk of cancer in CDKN2A germline mutation carriers.CDKN2A种系突变携带者患癌的前瞻性风险。
J Med Genet. 2004 Jun;41(6):421-4. doi: 10.1136/jmg.2004.019349.

p16-Leiden种系变体携带者患癌的前瞻性风险及烟草使用的影响。

Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant.

作者信息

Potjer Thomas P, Kranenburg Heidi E, Bergman Wilma, de Vos tot Nederveen Cappel Wouter H, van Monsjou Hester S, Barge-Schaapveld Daniela Q C M, Vasen Hans F A

机构信息

Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Eur J Hum Genet. 2015 May;23(5):711-4. doi: 10.1038/ejhg.2014.187. Epub 2014 Sep 17.

DOI:10.1038/ejhg.2014.187
PMID:25227142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4402641/
Abstract

The p16-Leiden germline variant in the CDKN2A gene is associated with a high risk of melanoma and pancreatic cancer. The aims of this study were to assess the risk of developing other cancers and to determine whether tobacco use would alter cancer risk in carriers of such a variant. We therefore prospectively evaluated individuals with a p16-Leiden germline variant, participating in a pancreatic surveillance programme, for the occurrence of cancer (n=150). Tobacco use was assessed at the start of the surveillance programme. We found a significantly increased risk for melanoma (relative risk (RR) 41.3; 95% confidence interval (CI) 22.9-74.6) and pancreatic cancer (RR 80.8; 95% CI 44.7-146). In addition, increased risks were found for cancers of the lip, mouth and pharynx (RR 18.8; 95% CI 6.05-58.2) and respiratory tumours (RR 4.56; 95% CI 1.71-12.1). Current smokers developed significantly more cancers of the lip, mouth and pharynx, respiratory system and pancreas compared with former and never-smokers. In conclusion, this study shows that carriers of a p16-Leiden variant have an increased risk of developing various types of cancer, and smoking significantly increases the risk of frequently occurring cancers. Smoking cessation should be an integral part of the management of p16-Leiden variant carriers.

摘要

CDKN2A基因中的p16-Leiden种系变体与黑色素瘤和胰腺癌的高风险相关。本研究的目的是评估发生其他癌症的风险,并确定吸烟是否会改变此类变体携带者的癌症风险。因此,我们对参与胰腺监测项目的p16-Leiden种系变体个体进行了前瞻性评估,以观察癌症的发生情况(n = 150)。在监测项目开始时评估吸烟情况。我们发现黑色素瘤(相对风险(RR)41.3;95%置信区间(CI)22.9 - 74.6)和胰腺癌(RR 80.8;95% CI 44.7 - 146)的风险显著增加。此外,还发现唇、口腔和咽癌(RR 18.8;95% CI 6.05 - 58.2)和呼吸道肿瘤(RR 4.56;95% CI 1.71 - 12.1)的风险增加。与既往吸烟者和从不吸烟者相比,目前吸烟者患唇、口腔和咽、呼吸系统和胰腺癌的比例显著更高。总之,本研究表明,p16-Leiden变体携带者发生各种类型癌症的风险增加,吸烟会显著增加常见癌症的风险。戒烟应成为p16-Leiden变体携带者管理的一个组成部分。